PASLI disease
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC
| PASLI disease | |
|---|---|
| File:Proposed model for the effects of activating substitutions in p110δ.png | |
| Synonyms | Activated PI3K-δ syndrome (APDS) |
| Pronounce | |
| Specialty | Immunology |
| Symptoms | Recurrent infections, lymphoproliferation, autoimmunity |
| Complications | N/A |
| Onset | Childhood |
| Duration | Chronic |
| Types | N/A |
| Causes | Mutations in the PIK3CD or PIK3R1 genes |
| Risks | |
| Diagnosis | Genetic testing, clinical evaluation |
| Differential diagnosis | Common variable immunodeficiency, X-linked agammaglobulinemia |
| Prevention | |
| Treatment | Immunoglobulin replacement therapy, targeted therapies |
| Medication | Sirolimus, Lenalidomide |
| Prognosis | Variable, depending on severity and treatment |
| Frequency | Rare |
| Deaths | |
PASLI disease (also known as Activated PI3K-δ Syndrome) is a rare primary immunodeficiency disorder characterized by mutations in the PIK3CD or PIK3R1 genes. These mutations lead to hyperactivation of the PI3K pathway, resulting in immune dysregulation.
Presentation[edit]
Patients with PASLI disease typically present with recurrent sinopulmonary infections, lymphadenopathy, and hepatosplenomegaly. Other common features include autoimmunity, enteropathy, and an increased risk of lymphoma.
Genetics[edit]
PASLI disease is caused by mutations in the PIK3CD gene, which encodes the p110δ catalytic subunit of phosphoinositide 3-kinase, or the PIK3R1 gene, which encodes the p85α regulatory subunit. These mutations result in the constitutive activation of the PI3K pathway, leading to immune cell dysfunction.
Diagnosis[edit]
Diagnosis of PASLI disease involves genetic testing to identify mutations in the PIK3CD or PIK3R1 genes. Additional diagnostic criteria include clinical features such as recurrent infections, lymphoproliferation, and autoimmunity.
Treatment[edit]
Treatment for PASLI disease is primarily supportive and includes the use of immunoglobulin replacement therapy, antibiotic prophylaxis, and management of autoimmune complications. Targeted therapies, such as PI3K inhibitors, are being investigated as potential treatments.
Prognosis[edit]
The prognosis for individuals with PASLI disease varies depending on the severity of the symptoms and the response to treatment. Early diagnosis and appropriate management are crucial for improving outcomes.
See also[edit]
 | This genetic disorder article is a stub. You can help WikiMD by expanding the page. |
